Featured Articles

  1. Five Reasons The Hub-And-Spoke Model Is Gaining Traction In Biotech 6/3/2026

    Biotech is shifting to hub-and-spoke models to share infrastructure, reduce single-asset risk, and build repeatable engines for innovation.

  2. Why Drug Repurposing Might Be Biotech's Most Capital-Efficient Strategy 5/29/2026

    In a tighter capital environment, drug repurposing offers biotech a more disciplined path to clinical progress and operational efficiency, writes Paul Michaels. 

  3. The Bond Factor: Relationship-Driven Performance 5/27/2026

    Trust-driven relationships, not strategy alone, power performance, helping leaders drive change, collaboration, and resilience, writes Wanda Shoer.

  4. Patient Data Now Has Borders. Does Your Life Sciences Strategy? 5/22/2026

    As patient data rules tighten globally, life sciences companies should treat data sovereignty as a strategic opportunity to improve trial operations and partnerships.

  5. Why The Best Biotech Leaders Take It Personally 5/20/2026

    Personal investment isn’t a liability in biotech leadership, but rather, a competitive advantage, writes Lisa Ricciardi, CEO of Cognition Therapeutics.

  6. Beyond GLP-1s: Competing In The Era Of Consumerized Therapeutics 5/15/2026

    GLP-1 therapies created a consumer-driven market for pharmaceuticals that pairs digital access, partnerships, and retention tools with traditional launch models.

  7. A Door Ajar: FDA's Final SIUU Guidance And Off-Label Communications 5/13/2026

    FDA’s final SIUU guidance loosens some off-label communication rules, but drugmakers still face strict compliance demands to stay within the safe harbor. 

  8. 5 Critical Risks With The FDA's Real-Time Trial Monitoring 5/8/2026

    Life science legal experts Kimberly Chew and Odette Hauke cover the FDA proof-of-concept real-time clinical trials (RTCTs) and expose five major issues that must be addressed before the pilot expands.

  9. From Copilot To Autopilot: Why Biopharma Must Stop Renting Its Future 5/5/2026

    With AI, the tools are ready and the budgets are allocated, but they are flowing to the wrong places, write Romi Singh, Ph.D. and Jared R. Auclair, Ph.D. 

  10. How Commercial Leaders Can Optimize Their Relationships With The Board 4/30/2026

    The commercial leader/board dynamic will matter even more as pricing pressures and policy complexity increase, writes Beren Therapeutics' Bennett Smith.